Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide vs Lamotrigine as Add‑on Therapy for Refractory Partial Seizures
2016-004954-13Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in epilepsy comparing Zonisamide add-on arm with Lamotrigine add-on arm (2 arms). Primary endpoint: Percentage change in monthly seizure frequency.
02
Drugs
zonisamidelamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2016-004954-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004954-13.